Infant Formula Recall Retirada del mercado de fórmula infantil

ALERT: ByHeart Recalls Whole Nutrition Infant Formula. Read more

AVISO IMPORTANTE: ByHeart retira del mercado su fórmula infantil Whole Nutrition. Aprender más

Transportation Update Actualización de transporte

Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.

Learn more here

For other questions, please call Member Services at the number on the back of your member ID card.

A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).

Obtenga más información AQUI

Si tiene otras preguntas, llame a Servicios para Miembros al número que aparece en la parte posterior de su tarjeta de identificación del miembro.

Search

Sarepta Therapeutics Provides Clinical Updates for ELEVIDYS

Date: November 25, 2025

Attention: Providers

Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that the Health and Human Services Commission (HHSC) has been made aware of several key updates for the drug:

  • A boxed warning for the risk of acute serious liver injury and acute liver failure
  • Removal of the non-ambulatory indication from the “Indication and Usage” section of the Prescribing Information
  • Expanded guidance for prescribers, including a modified pre- and post-infusion oral corticosteroids regimen, and enhanced monitoring recommendations every week for 3 months post-infusion
  • A new Warnings & Precaution regarding increased susceptibility to serious infections due to immunosuppression

Background: ELEVIDYS (Delandistrogene moxeparvovec-rokl) (HCPCS code J1413) is an adeno-associated virus vector-based gene therapy indicated for the treatment of individuals aged four years or older with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene.

Previously posted TCHP communication on this important topic is available by clicking here.

Next step for Providers: Providers should follow the guidance found in this communication and the following link elevidys.com/pi for prescribing information.

If you have any questions, please email Provider Relations at providerrelations@texaschildrens.org. 

For access to all provider alerts: www.texaschildrenshealthplan.org/provideralerts.